Salmeterol
- Generic Name
- Salmeterol
- Brand Names
- Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 89365-50-4
- Unique Ingredient Identifier
- 2I4BC502BT
- Background
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure i...
- Indication
用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
- Associated Therapies
- -
Salmeterol Effect on Exercise Performance
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 36
- Registration Number
- NCT06655012
- Locations
- 🇩🇰
August Krogh Building, Copenhagen, Denmark
ANTES B+ Clinical Trial
- Conditions
- Interventions
- Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30DDrug: BrimicaDrug: DuaklirDrug: UltibroDrug: UlunarDrug: XoternaDrug: AnoroDrug: LaventairDrug: Spiolto RespimatDrug: YanimoDrug: ForadilDrug: BroncoralDrug: Formoterol stadaDrug: OxisDrug: FormatrisDrug: Formoterol AldoDrug: OnbrezDrug: OslifDrug: HirobrizDrug: StriverdiDrug: BeglanDrug: BetamicanDrug: InaspirDrug: SereventDrug: SoltelDrug: EkliraDrug: BretarisDrug: SeebriDrug: TovanorDrug: EnurevDrug: SpirivaDrug: TavulusDrug: SirkavaDrug: BraltusDrug: GregalDrug: IncruseDrug: Rolufta
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Fundacio Privada Mon Clinic Barcelona
- Target Recruit Count
- 1028
- Registration Number
- NCT06282861
- Locations
- 🇪🇸
Hospital Clínic Barcelona, Barcelona, Catalunya, Spain
Replication of the POET-COPD Trial in Healthcare Claims Data
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 8716
- Registration Number
- NCT05083429
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 302
- Registration Number
- NCT03240575
- Locations
- 🇺🇸
Pulmonary Rsrch Inst of SE MI, Farmington Hills, Michigan, United States
🇺🇸Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
Cardiovascular Function in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 76
- Registration Number
- NCT03055988
- Locations
- 🇩🇪
Universitätsklinikum Bonn AöR, Bonn, Germany
🇩🇪Klinische Forschung Berlin GbR, Berlin, Germany
🇩🇪Praxis Dr. med. Claus Keller, Frankfurt, Germany
Pharmacological Properties of Salmeterol
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 11
- Registration Number
- NCT02558088
- Locations
- 🇩🇰
Bispebjerg Hospital, Copenhagen, Select State, Denmark
A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma
- Conditions
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 423
- Registration Number
- NCT02446418
- Locations
- 🇩🇪
GSK Investigational Site, Magdeburg, Germany
In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02256722
Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 97
- Registration Number
- NCT02242253
Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Kindeva Drug Delivery
- Target Recruit Count
- 52
- Registration Number
- NCT02232087
- Locations
- 🇬🇧
Quotient Clinical Ltd, Ruddington, Nottingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.